Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies

Purpose: Ruxolitinib (selective Janus kinase [JAK] 1 and JAK2 inhibitor) cream demonstrated efficacy and safety in patients with atopic dermatitis (AD) in the phase 3 TRuE-AD studies. In TRuE-AD1/TRuE-AD2 (NCT03745638/NCT03745651), adults and adolescents with mild to moderate AD were randomized to a...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Eric L. Simpson, Robert Bissonnette, Zelma C. Chiesa Fuxench, Howard Kallender, Daniel Sturm, Haobo Ren, Linda F. Stein Gold
Format:	Artigo
Język:	Inglês
Wydane:	Taylor & Francis Group 2024-12-01
Seria:	Journal of Dermatological Treatment
Hasła przedmiotowe:	Atopic dermatitis head and neck JAK inhibitor ruxolitinib cream
Dostęp online:	https://www.tandfonline.com/doi/10.1080/09546634.2024.2310633
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!